These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 32844093)
1. Pimavanserin for the treatment of psychosis in Alzheimer's disease: A literature review. Srinivasan S; Tampi RR; Balaram K; Kapoor A World J Psychiatry; 2020 Jul; 10(7):162-174. PubMed ID: 32844093 [TBL] [Abstract][Full Text] [Related]
2. A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. Kurhan F; Akın M Curr Alzheimer Res; 2023; 20(6):403-408. PubMed ID: 37641988 [TBL] [Abstract][Full Text] [Related]
3. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. Ballard C; Youakim JM; Coate B; Stankovic S J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S; Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684 [TBL] [Abstract][Full Text] [Related]
11. Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature. Touma KTB; Touma DC Ment Health Clin; 2017 Sep; 7(5):230-234. PubMed ID: 29955528 [TBL] [Abstract][Full Text] [Related]
12. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F F1000Res; 2020; 9():. PubMed ID: 32695312 [TBL] [Abstract][Full Text] [Related]
13. Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis. Yunusa I; El Helou ML; Alsahali S Front Pharmacol; 2020; 11():87. PubMed ID: 32174828 [TBL] [Abstract][Full Text] [Related]
14. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
15. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. Sellers J; Darby RR; Farooque A; Claassen DO Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099 [TBL] [Abstract][Full Text] [Related]
16. Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study. Alva G; Cubała WJ; Berrio A; Coate B; Abler V; Pathak S J Alzheimers Dis; 2024; 98(1):265-274. PubMed ID: 38427485 [TBL] [Abstract][Full Text] [Related]
17. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Sahli ZT; Tarazi FI Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301 [TBL] [Abstract][Full Text] [Related]